PDF-US 2009H1N1 Vaccine StrategyVer 20_051809

MastrVrusSed Pep Vrus Reference Sain Pep Clinical InvestigationalLotMf ClinicalIsolatonSmple Vaccine Distribution Administration C o m m e r c i a l S c a l e B u l k A n t i g e n M anufactur. 1 What is live attenuated influenza vaccine LAIV 2 Why is LAIV an intranasal spray 3 Has LAIV been well studied 4 Why is LAIV not approved for use in Introduction. . Rotavirus . vaccines lead to significant reductions in severe and fatal diarrhea in both vaccinated and unvaccinated children. Rotavirus vaccines are saving lives and improving health in countries where children have access to them. . Authors Team:. . Johnny . Heald. . (Email: . jheald@opinion.co.uk). Dr. Sara . Gilani. . (. sigilani@hotmail.com). (in collaboration with Professor Heidi Larson of London school of Hygiene and Tropical Medicine, London University). “. T. he Captain of Death” -- Osler. History. 1881. Louis . P. asteur discovers the . pneumococcus. bacterium. 1886. Gold mining begins in South Africa. 1895. . Pneumococcus. identified as the cause of epidemic pneumonia that kills 35% of miners who are infected. Industry Perspective for 2014-15 NH Vaccine Supply. The FDA CBER requested this annual summary of information from influenza vaccine manufacturers supplying the U.S., for purposes of a general presentation to the VRBPAC. This summary has been prepared  from a variety of public sources, and was reviewed by AstraZeneca, bioCSL, GSK, Novartis, Protein Sciences, and Sanofi Pasteur.. 10. th. Measles Initiative Meeting. September 13-14, 2011, . Washington DC. Susan. E. Reef, CDC/GID/DEEB. Peter M. Strebel, WHO/HQ/IVB/EPI. Outline. Global and regional status . CRS burden. Vaccine uptake and regional goals. Presentation to: . Presented by:. Date:. Disclosure Statements. Neither . the planners of this session nor I have any financial relationship with pharmaceutical companies, biomedical device manufacturers, or corporations whose products and services are related to the vaccines we discuss.. Presentation to: . Presented by:. Date:. Disclosure Statements. Neither the planners of this session nor I have any financial relationship with pharmaceutical companies, biomedical device manufacturers, or corporations whose products and services are related to the vaccines we discuss.. . R. esearch. report on knowledge, attitudes, beliefs and practices. 2016. . Dulamsuren. . S . Jargalsaikhan. D . Tsetsegdary. . G. Purpose .  . Assess . knowledge, attitudes, beliefs and practices to vaccine uptake, and factors and constrains that affecting the vaccine hesitancy among parents/caregivers and . Presentation to: . Presented by:. Date:. Disclosure Statements. Neither the planners of this session nor I have any financial relationship with pharmaceutical companies, biomedical device manufacturers, or corporations whose products and services are related to the vaccines we discuss.. Alexis R. Santos Lozada, MA. Diego Caraballo. Jos. é N. Caraballo, PhD. Introduction . Human Papillomavirus is one of the most common sexually transmitted infections in the United States.. This infection has been catalogued as a requirement for the development of cervical cancer later in life.. Training for . I. nactivated. . P. oliovirus Vaccine (IPV) introduction. Learning objectives. At the end of the module, the participant will be able to:. Identify the necessary steps to assure good vaccine quality. . Zimbabwe. Where Are We?. By . M.N Munyoro, WHO/ NPO/EPI. Presentation to The Health Cluster. . 12/11/13 . The . pathogen particles are destroyed and cannot divide, but the pathogens maintain some of their integrity to be recognized by the immune system and evoke an adaptive immune response. . .. Immune response.